Tango Therapeutics (TNGX) Other financing activities (2020 - 2026)
Tango Therapeutics (TNGX) recorded quarterly Other financing activities of $537000.0 in Q1 2026, up 752.38% quarter-over-quarter from $63000.0 in Q4 2023.
Tango Therapeutics (TNGX) Other financing activities (2020 - 2026) Analysis & Trends
Tango Therapeutics' Other financing activities history runs 3 years deep, the most recent figure standing at $537000.0 for Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $537000.0; the TTM figure through Mar 2026 stood at $4.2 million (changed N/A YoY), while the FY2025 annual figure was $36000.0, changed N/A from the prior year.
- Other financing activities was $537000.0 for Q1 2026 at Tango Therapeutics, up from $63000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $537000.0 in Q1 2026 to a low of $63000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 537,000.00 |
| Mar 31, 2026 | 537,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Dec 31, 2020 | 3.59 Mn |
| Dec 31, 2020 | 3.59 Mn |
| Sep 30, 2020 | 3.59 Mn |
| Sep 30, 2020 | 3.59 Mn |